S K Feseke1,2, J St-Laurent1, E Anassour-Sidi1, P Ayotte1,2,3, M Bouchard4, P Levallois1,2,3. 1. Axe santé des populations et pratiques optimales en santé, Centre de recherche du CHU de Québec, Québec, Quebec, Canada. 2. Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, Quebec, Canada. 3. Direction de la santé environnementale et de la toxicologie, Institut national de santé publique du Québec, Québec, Quebec, Canada. 4. Département de santé environnementale et santé au travail, Chaire d'analyse et de gestion des risques toxicologiques, École de santé publique, Université de Montréal, Montréal, Quebec, Canada.
Abstract
INTRODUCTION: Inorganic arsenic and its metabolites are considered dangerous to human health. Although several studies have reported associations between low-level arsenic exposure and diabetes mellitus in the United States and Mexico, this association has not been studied in the Canadian population. We evaluated the association between arsenic exposure, as measured by total arsenic concentration in urine, and the prevalence of type 2 diabetes (T2D) in 3151 adult participants in Cycle 1 (2007-2009) of the Canadian Health Measures Survey (CHMS). METHODS: All participants were tested to determine blood glucose and glycated hemoglobin. Urine analysis was also performed to measure total arsenic. In addition, participants answered a detailed questionnaire about their lifestyle and medical history. We assessed the association between urinary arsenic levels and T2D and prediabetes using multivariate logistic regression while adjusting for potential confounders. RESULTS: Total urinary arsenic concentration was positively associated with the prevalence of T2D and prediabetes: adjusted odds ratios were 1.81 (95% CI: 1.12-2.95) and 2.04 (95% CI: 1.03-4.05), respectively, when comparing the highest (fourth) urinary arsenic concentration quartile with the lowest (first) quartile. Total urinary arsenic was also associated with glycated hemoglobin levels in people with untreated diabetes. CONCLUSION: We found significant associations between arsenic exposure and the prevalence of T2D and prediabetes in the Canadian population. Causal inference is limited due to the cross-sectional design of the study and the absence of long-term exposure assessment.
INTRODUCTION: Inorganic arsenic and its metabolites are considered dangerous to human health. Although several studies have reported associations between low-level arsenic exposure and diabetes mellitus in the United States and Mexico, this association has not been studied in the Canadian population. We evaluated the association between arsenic exposure, as measured by total arsenic concentration in urine, and the prevalence of type 2 diabetes (T2D) in 3151 adult participants in Cycle 1 (2007-2009) of the Canadian Health Measures Survey (CHMS). METHODS: All participants were tested to determine blood glucose and glycated hemoglobin. Urine analysis was also performed to measure total arsenic. In addition, participants answered a detailed questionnaire about their lifestyle and medical history. We assessed the association between urinary arsenic levels and T2D and prediabetes using multivariate logistic regression while adjusting for potential confounders. RESULTS: Total urinary arsenic concentration was positively associated with the prevalence of T2D and prediabetes: adjusted odds ratios were 1.81 (95% CI: 1.12-2.95) and 2.04 (95% CI: 1.03-4.05), respectively, when comparing the highest (fourth) urinary arsenic concentration quartile with the lowest (first) quartile. Total urinary arsenic was also associated with glycated hemoglobin levels in people with untreated diabetes. CONCLUSION: We found significant associations between arsenic exposure and the prevalence of T2D and prediabetes in the Canadian population. Causal inference is limited due to the cross-sectional design of the study and the absence of long-term exposure assessment.
Entities:
Keywords:
Canadian Health Measures Survey; population survey; type 2 diabetes; urinary arsenic
Authors: Shu-Li Wang; Feng-Hsiang Chang; Saou-Hsing Liou; Hsiu-Jen Wang; Wan-Fen Li; Dennis P H Hsieh Journal: Environ Int Date: 2007-05-03 Impact factor: 9.621
Authors: Kefeng Yang; Pengcheng Xun; Mercedes Carnethon; April P Carson; Liping Lu; Jie Zhu; Ka He Journal: Environ Res Date: 2019-01-25 Impact factor: 6.498
Authors: Miranda J Spratlen; Maria Grau-Perez; Jason G Umans; Joseph Yracheta; Lyle G Best; Kevin Francesconi; Walter Goessler; Teodoro Bottiglieri; Mary V Gamble; Shelley A Cole; Jinying Zhao; Ana Navas-Acien Journal: Environ Res Date: 2018-09-27 Impact factor: 6.498
Authors: Shadassa Ourshalimian; Abu Mohd Naser; Mahbubur Rahman; Solaiman Doza; Jennifer Stowell; K M Venkat Narayan; Mohammad Shamsudduha; Matthew O Gribble Journal: Environ Res Date: 2018-12-21 Impact factor: 6.498
Authors: Miranda J Spratlen; Maria Grau-Perez; Lyle G Best; Joseph Yracheta; Mariana Lazo; Dhananjay Vaidya; Poojitha Balakrishnan; Mary V Gamble; Kevin A Francesconi; Walter Goessler; Shelley A Cole; Jason G Umans; Barbara V Howard; Ana Navas-Acien Journal: Am J Epidemiol Date: 2018-08-01 Impact factor: 4.897
Authors: Maria Grau-Perez; Chin-Chi Kuo; Matthew O Gribble; Poojitha Balakrishnan; Miranda Jones Spratlen; Dhananjay Vaidya; Kevin A Francesconi; Walter Goessler; Eliseo Guallar; Ellen K Silbergeld; Jason G Umans; Lyle G Best; Elisa T Lee; Barbara V Howard; Shelley A Cole; Ana Navas-Acien Journal: Environ Health Perspect Date: 2017-12-20 Impact factor: 9.031